40 related articles for article (PubMed ID: 22995025)
1. The puzzles surrounding the impact of face masks on 6-minute walking distance in pulmonary hypertension.
Ma JL; Wang AY; Lu D; Cheng CY; Jing ZC
Eur Respir J; 2024 May; 63(5):. PubMed ID: 38754950
[No Abstract] [Full Text] [Related]
2. Reply to: The puzzles surrounding the impact of face masks on 6-minute walking distance in pulmonary hypertension.
Wissmüller M; Wartner V; Hohmann C; Adler J; Kramer T; Hellmich M; Gerhardt F; Baldus S; Rosenkranz S
Eur Respir J; 2024 May; 63(5):. PubMed ID: 38754949
[No Abstract] [Full Text] [Related]
3. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.
McDonald CM; Henricson EK; Abresch RT; Florence J; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz SW
Muscle Nerve; 2013 Sep; 48(3):357-68. PubMed ID: 23674289
[TBL] [Abstract][Full Text] [Related]
4. Digital Endpoints: Definition, Benefits, and Current Barriers in Accelerating Development and Adoption.
Landers M; Dorsey R; Saria S
Digit Biomark; 2021; 5(3):216-223. PubMed ID: 34703976
[TBL] [Abstract][Full Text] [Related]
5. Fick principle and exercise pulmonary hemodynamic determinants of the six-minute walk distance in pulmonary hypertension.
Joseph P; Oliveira RKF; Eslam RB; Agarwal M; Waxman AB; Systrom DM
Pulm Circ; 2020; 10(3):2045894020957576. PubMed ID: 32994925
[TBL] [Abstract][Full Text] [Related]
6. Schistosomiasis-associated pulmonary arterial hypertension: survival in endemic area in Brazil.
Piscoya Roncal CG; Mendes AA; Muniz MTC; de Oliveira SA; do Valle Neto LM; de Vasconcellos Piscoya NA; Góes GHB; Sobral Filho DC; Gomberg-Maitland M
Int J Cardiol Heart Vasc; 2019 Dec; 25():100373. PubMed ID: 31720370
[TBL] [Abstract][Full Text] [Related]
7. Six-Minute Walk Test: Clinical Role, Technique, Coding, and Reimbursement.
Agarwala P; Salzman SH
Chest; 2020 Mar; 157(3):603-611. PubMed ID: 31689414
[TBL] [Abstract][Full Text] [Related]
8. The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry.
Billings CG; Lewis R; Hurdman JA; Condliffe R; Elliot CA; Thompson AAR; Smith IA; Austin M; Armstrong IJ; Hamilton N; Charalampopoulos A; Sabroe I; Swift AJ; Rothman AM; Wild JM; Lawrie A; Waterhouse JC; Kiely DG
Pulm Circ; 2019; 9(2):2045894019848649. PubMed ID: 30997865
[TBL] [Abstract][Full Text] [Related]
9. Haemodynamically Derived Pulmonary Artery Pulsatility Index Predicts Mortality in Pulmonary Arterial Hypertension.
Mazimba S; Welch TS; Mwansa H; Breathett KK; Kennedy JLW; Mihalek AD; Harding WC; Mysore MM; Zhuo DX; Bilchick KC
Heart Lung Circ; 2019 May; 28(5):752-760. PubMed ID: 29748060
[TBL] [Abstract][Full Text] [Related]
10. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.
Souza R; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Le Brun FO; Mehta S; Perchenet L; Pulido T; Sastry BKS; Sitbon O; Torbicki A; Rubin LJ; Simonneau G
PLoS One; 2018; 13(3):e0193226. PubMed ID: 29590122
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary Hypertension and Precision Medicine through the "Omics" Looking Glass.
Barnes JW; Dweik RA
Am J Respir Crit Care Med; 2017 Jun; 195(12):1558-1560. PubMed ID: 28617089
[No Abstract] [Full Text] [Related]
12. Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.
Newman JH; Rich S; Abman SH; Alexander JH; Barnard J; Beck GJ; Benza RL; Bull TM; Chan SY; Chun HJ; Doogan D; Dupuis J; Erzurum SC; Frantz RP; Geraci M; Gillies H; Gladwin M; Gray MP; Hemnes AR; Herbst RS; Hernandez AF; Hill NS; Horn EM; Hunter K; Jing ZC; Johns R; Kaul S; Kawut SM; Lahm T; Leopold JA; Lewis GD; Mathai SC; McLaughlin VV; Michelakis ED; Nathan SD; Nichols W; Page G; Rabinovitch M; Rich J; Rischard F; Rounds S; Shah SJ; Tapson VF; Lowy N; Stockbridge N; Weinmann G; Xiao L
Am J Respir Crit Care Med; 2017 Jun; 195(12):1661-1670. PubMed ID: 28430547
[TBL] [Abstract][Full Text] [Related]
13. Value of impedance cardiography during 6-minute walk test in pulmonary hypertension.
Tonelli AR; Alkukhun L; Arelli V; Ramos J; Newman J; McCarthy K; Pichurko B; Minai OA; Dweik RA
Clin Transl Sci; 2013 Dec; 6(6):474-80. PubMed ID: 24330692
[TBL] [Abstract][Full Text] [Related]
14. The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension.
Gaine S; Simonneau G
Eur Respir Rev; 2013 Dec; 22(130):487-94. PubMed ID: 24293464
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics.
Duarte JD; Hanson RL; Machado RF
Future Cardiol; 2013 May; 9(3):335-49. PubMed ID: 23668740
[TBL] [Abstract][Full Text] [Related]
16. The pulmonary hypertension academic research consortium.
Rich S
Pulm Circ; 2013 Jan; 3(1):203-5. PubMed ID: 23662198
[No Abstract] [Full Text] [Related]
17. The 6-minute walk test as a primary endpoint in clinical trials for pulmonary hypertension.
Rich S
J Am Coll Cardiol; 2012 Sep; 60(13):1202-3. PubMed ID: 22995025
[No Abstract] [Full Text] [Related]
18. Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole?
Farber HW
Circulation; 2012 Jul; 126(3):258-60. PubMed ID: 22696078
[No Abstract] [Full Text] [Related]
19. The 6-minute walk test in pulmonary arterial hypertension: how far is enough?
Rubin LJ
Am J Respir Crit Care Med; 2012 Sep; 186(5):396-7. PubMed ID: 22942342
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
